mir-101-3p Downregulation Promotes Fibrogenesis by Facilitating Hepatic Stellate Cell Transdifferentiation During Insulin Resistance

Increased Expression of Circulating microRNA 101-3p in Type 1 Diabetes Patients: New Insights Into miRNA-Regulated Pathophysiological Pathways for Type 1 Diabetes

(2019) Aritania S. Santos et al.   Frontiers in Immunology

Molecular Insight into the Interaction between Epigenetics and Leptin in Metabolic Disorders

(2019) Adam Wróblewski et al.   Nutrients

The Role of MicroRNAs in Hepatocellular Carcinoma

(2018) Xin Xu et al.   Journal of Cancer

miRNA Signature in NAFLD: A Turning Point for a Non-Invasive Diagnosis

(2018) Paola Dongiovanni et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

A Nutrigenomic Approach to Non-Alcoholic Fatty Liver Disease

(2017) Paola Dongiovanni et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

MicroRNA-101 attenuates pulmonary fibrosis by inhibiting fibroblast proliferation and activation

(2017) Chaoqun Huang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The prognostic value of decreased miR-101 in various cancers: a meta-analysis of 12 studies

(2017) Jianpei Hu et al.   OncoTargets and Therapy

Animal Models of Nonalcoholic Fatty Liver Disease—A Starter’s Guide

(2017) Mikhaïl Van Herck et al.   Nutrients

Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes

(2016) Zobair M. Younossi et al.   HEPATOLOGY

MiR-101 Targets the EZH2/Wnt/β-Catenin the Pathway to Promote the Osteogenic Differentiation of Human Bone Marrow-Derived Mesenchymal Stem Cells

(2016) Hongrui Wang et al.   Scientific Reports

miR-101 represses lung cancer by inhibiting interaction of fibroblasts and cancer cells by down-regulating CXCL12

(2015) Jian Zhang et al.   BIOMEDICINE & PHARMACOTHERAPY

Nonalcoholic Steatohepatitis Is the Second Leading Etiology of Liver Disease Among Adults Awaiting Liver Transplantation in the United States

(2015) Robert J. Wong et al.   GASTROENTEROLOGY

Pathogenesis of Selective Insulin Resistance in Isolated Hepatocytes

(2015) Joshua R. Cook et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management

(2015) Stuart McPherson et al.   JOURNAL OF HEPATOLOGY

NAFLD: A multisystem disease

(2015) Christopher D. Byrne et al.   JOURNAL OF HEPATOLOGY

miR-101a and miR-30b contribute to inflammatory cytokine-mediated β-cell dysfunction

(2015) Ying Zheng et al.   LABORATORY INVESTIGATION

Identification of Circulating miR-101, miR-375 and miR-802 as Biomarkers for Type 2 Diabetes

(2015) Chigusa Higuchi et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

MicroRNA-101 sensitizes hepatocellular carcinoma cells to doxorubicin-induced apoptosis via targeting Mcl-1

(2015) HAIFEI HE et al.   Molecular Medicine Reports

The role of insulin resistance in nonalcoholic steatohepatitis and liver disease development – a potential therapeutic target?

(2015) Paola Dongiovanni et al.   Expert Review of Gastroenterology & Hepatology

Systemic Delivery of MicroRNA-101 Potently Inhibits Hepatocellular Carcinoma In Vivo by Repressing Multiple Targets

(2015) Fang Zheng et al.   PLoS Genetics

Transfection of microRNA Mimics Should Be Used with Caution

(2015) Hyun Yong Jin et al.   Frontiers in Genetics

MicroRNA-101 targets EZH2, MCL-1 and FOS to suppress proliferation, invasion and stem cell-like phenotype of aggressive endometrial cancer cells

(2015) Yosuke Konno et al.   Oncotarget

Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis

(2014) Carlos J Pirola et al.   GUT

The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease

(2014) Maryann Maximos et al.   HEPATOLOGY

MicroRNA-101 suppresses liver fibrosis by targeting the TGFβ signalling pathway

(2014) Xiaolong Tu et al.   JOURNAL OF PATHOLOGY

MicroRNAs as controlled systems and controllers in non-alcoholic fatty liver disease

(2014) Nadia Panera   WORLD JOURNAL OF GASTROENTEROLOGY

Influence of miRNA in insulin signaling pathway and insulin resistance: micro-molecules with a major role in type-2 diabetes

(2014) Chiranjib Chakraborty et al.   Wiley Interdisciplinary Reviews-RNA

MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity

(2013) Leibo Xu et al.   JOURNAL OF HEPATOLOGY

miR-101 inhibits autophagy and enhances cisplatin-induced apoptosis in hepatocellular carcinoma cells

(2013) YONGHUA XU et al.   ONCOLOGY REPORTS

MicroRNA-101 Inhibited Postinfarct Cardiac Fibrosis and Improved Left Ventricular Compliance via the FBJ Osteosarcoma Oncogene/Transforming Growth Factor-β1 Pathway

(2012) Zhenwei Pan et al.   CIRCULATION

MiR-101 Is Involved in Human Breast Carcinogenesis by Targeting Stathmin1

(2012) Rui Wang et al.   PLoS One

Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease

(2010) P. Dongiovanni et al.   GUT

MicroRNA-101 Targets MAPK Phosphatase-1 To Regulate the Activation of MAPKs in Macrophages

(2010) Q.-Y. Zhu et al.   JOURNAL OF IMMUNOLOGY

MicroRNA-101, Down-regulated in Hepatocellular Carcinoma, Promotes Apoptosis and Suppresses Tumorigenicity

(2009) H. Su et al.   CANCER RESEARCH

Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes

(2008) Anna Ludovica Fracanzani et al.   HEPATOLOGY

Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet

(2008) Mary E. Rinella et al.   JOURNAL OF LIPID RESEARCH

The impact of microRNAs on protein output

(2008) Daehyun Baek et al.   NATURE

Genomic Loss of microRNA-101 Leads to Overexpression of Histone Methyltransferase EZH2 in Cancer

(2008) S. Varambally et al.   SCIENCE